ArticleThe Journal of infectious diseases2011
Serum antibody response following genital {alpha}9 human papillomavirus infection in young men.
Article in The Journal of infectious diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 61 citations in OpenAlex.
- Impact of switching from a quadrivalent to a nonavalent HPV vaccine on HPV infections and cervical cancer in Colombia: a mathematical modelling study.Lancet regional health. Americas · 2026Article
- Naturally Acquired Genotype-Specific HPV Seroreactivity and Subsequent HPV Detection Among Heterosexual Partners.Journal of medical virology · 2025Article
- Review
- Low-Grade Cervical Intraepithelial Neoplasia (CIN1) Evolution: Analysis of Opportunistic Preventive Vaccination Role.Vaccines · 2023Article
- Article
- Review
- Serum Anti-HPV Antibody Titer as a Marker of Vaccine Effectiveness in Males with Genital Infection.Vaccines · 2020Article
- Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003-2010.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.BMC infectious diseases · 2019Article
- Should female sex workers be offered HPV vaccination?Human vaccines & immunotherapeutics · 2019Review
- Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.Clinics in colon and rectal surgery · 2018Review
- Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations.Papillomavirus research (Amsterdam, Netherlands) · 2017Article
- Tumour virus vaccines: hepatitis B virus and human papillomavirus.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2017Review
- High-risk human papillomavirus seroprevalence in men and women of six different ethnicities in Amsterdam, the Netherlands: The HELIUS study.Papillomavirus research (Amsterdam, Netherlands) · 2017Article
- Re-detection vs. new acquisition of high-risk human papillomavirus in mid-adult women.International journal of cancer · 2016Article
- HPV vaccination for MSM: Synthesis of the evidence and recommendations from the Québec Immunization Committee.Human vaccines & immunotherapeutics · 2016Review
- Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study.Scientific reports · 2016Article
- Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.Sexually transmitted diseases · 2016Article
- Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006.The Journal of infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Background. Although the prevalence of human papillomavirus (HPV) genital infection is similarly high in males and females, seroprevalence is lower in males. This study assessed rates and determinants of seroconversion after detection of genital HPV infection in young men. Methods. We investigated HPV type-specific seroconversion in a cohort of heterosexual male university students who had an α9 HPV type (HPV-16, -31, -33, -35, -52, -58, or -67) detected in the genital tract (n = 156). HPV DNA and antibodies were detected and typed using liquid bead-based multiplex assays. We calculated seroconversion using Kaplan-Meier survival analysis. Cox proportional hazards models with generalized estimating equations were used to examine associations with seroconversion. Results. Within 24 months of detecting genital HPV infection, type-specific seroconversion ranged from 4% for HPV-52 to 36% for HPV-31. HPV-16 seroconversion at 24 months was 13% (95% confidence interval [CI], 7%-25%). Among incident HPV infections, ever cigarette smoking and infection site(s) (shaft/scrotum and glans/urine vs shaft/scrotum or glans/urine only) were positively associated with type-specific seroconversion. Conclusions. For each of the α9 HPV types, type-specific seroconversion within 24 months was observed in 36% or less of infected men. Seroconversion might be related to cigarette smoking and genital site(s) infected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.